Overview
UTHR market data
Price History
UTHR price chart · 1M
- O
- 503.49
- H
- 505.78
- L
- 497.67
- C
- 498.40
- Vol
- 29,683.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $503.49
- Previous Close
- $500.28
- Day High
- $505.78
- Day Low
- $497.67
- 52 Week High
- $580.13
- 52 Week Low
- $477.34
- 7 Day Return
- -1.71%
- 30 Day Return
- -1.96%
- 90 Day Return
- -7.10%
- 1 Year Return
- -11.66%
- Daily Notional Volume
- $14.8M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 16.46 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $27.86 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.51 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 41.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $395.00 – $609.35 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $21.6B · P/B 2.96 · P/S 6.84.
Company News
10 captured
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?Zacks Investment Research ·
8-K filing — UNITED THERAPEUTICS Corp (UTHR)SEC EDGAR ·
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary FibrosisZacks Investment Research ·
United Therapeutics Says FDA Accepts sNDA For Nebulized Tyvaso Inhalation Solution To Treat IPFBenzinga ·
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?Zacks Investment Research ·
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAHZacks Investment Research ·